nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymorphone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Oxymorphone—Hypotension—Leflunomide—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Oxymorphone—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Oxymorphone—Palpitations—Lisinopril—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Oxymorphone—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Oxymorphone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Oxymorphone—Loss of consciousness—Lisinopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Oxymorphone—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Oxymorphone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Oxymorphone—Visual disturbance—Methotrexate—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Oxymorphone—Anorexia—Mycophenolic acid—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Oxymorphone—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Oxymorphone—Tension—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Oxymorphone—Insomnia—Leflunomide—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Oxymorphone—Abdominal distension—Prednisone—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Oxymorphone—Chest pain—Lisinopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Oxymorphone—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Oxymorphone—Anxiety—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Oxymorphone—Dyspnoea—Leflunomide—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Oxymorphone—Hypotension—Mycophenolic acid—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Oxymorphone—Lethargy—Methotrexate—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Oxymorphone—Dyspepsia—Leflunomide—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Oxymorphone—Vomiting—Mometasone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Oxymorphone—Dry mouth—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Oxymorphone—Sweating increased—Prednisone—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Oxymorphone—Feeling abnormal—Azathioprine—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Oxymorphone—Asthenia—Captopril—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Oxymorphone—Dermatitis—Mometasone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Oxymorphone—Decreased appetite—Leflunomide—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Oxymorphone—Confusional state—Lisinopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Headache—Mometasone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Insomnia—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Fatigue—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Oxymorphone—Oedema—Lisinopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Oxymorphone—Pruritus—Captopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Oxymorphone—Constipation—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Oxymorphone—Pain—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Oxymorphone—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Oxymorphone—Somnolence—Mycophenolic acid—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Oxymorphone—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Oxymorphone—Shock—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Oxymorphone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Oxymorphone—Tachycardia—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Oxymorphone—Abdominal pain—Azathioprine—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Oxymorphone—Body temperature increased—Azathioprine—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Oxymorphone—Skin disorder—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Oxymorphone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Oxymorphone—Diarrhoea—Captopril—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Oxymorphone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Oxymorphone—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Oxymorphone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Oxymorphone—Feeling abnormal—Leflunomide—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Oxymorphone—Fatigue—Mycophenolic acid—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Oxymorphone—Nausea—Mometasone—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Oxymorphone—Anorexia—Lisinopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Oxymorphone—Constipation—Mycophenolic acid—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Oxymorphone—Pain—Mycophenolic acid—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Oxymorphone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Oxymorphone—Weight decreased—Prednisone—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Oxymorphone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Oxymorphone—Hypotension—Lisinopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Oxymorphone—Dizziness—Captopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Oxymorphone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Oxymorphone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Oxymorphone—Urticaria—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Oxymorphone—Abdominal pain—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Oxymorphone—Body temperature increased—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Oxymorphone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Oxymorphone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Oxymorphone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Oxymorphone—Hypersensitivity—Azathioprine—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Oxymorphone—Insomnia—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Oxymorphone—Vomiting—Captopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Oxymorphone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Oxymorphone—Dyspnoea—Lisinopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Oxymorphone—Dermatitis—Captopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Oxymorphone—Somnolence—Lisinopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Oxymorphone—Headache—Captopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Oxymorphone—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Oxymorphone—Dyspepsia—Lisinopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Oxymorphone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Oxymorphone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Oxymorphone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Oxymorphone—Decreased appetite—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Oxymorphone—Fatigue—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Oxymorphone—Shock—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Oxymorphone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Oxymorphone—Hypersensitivity—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Oxymorphone—Pain—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Oxymorphone—Constipation—Lisinopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Oxymorphone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Oxymorphone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Oxymorphone—Bradycardia—Prednisone—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Oxymorphone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Oxymorphone—Diarrhoea—Azathioprine—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Oxymorphone—Nausea—Captopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Oxymorphone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Oxymorphone—Asthenia—Leflunomide—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Oxymorphone—Hallucination—Prednisone—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Oxymorphone—Feeling abnormal—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Oxymorphone—Pruritus—Leflunomide—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Oxymorphone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Oxymorphone—Dizziness—Azathioprine—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Oxymorphone—Asthenia—Mycophenolic acid—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Oxymorphone—Diarrhoea—Leflunomide—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Oxymorphone—Urticaria—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Oxymorphone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Oxymorphone—Abdominal pain—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Oxymorphone—Body temperature increased—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Oxymorphone—Pruritus—Mycophenolic acid—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Oxymorphone—Vomiting—Azathioprine—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Oxymorphone—Pneumonia—Methotrexate—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Oxymorphone—Eye disorder—Prednisone—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Oxymorphone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Oxymorphone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Oxymorphone—Dermatitis—Azathioprine—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Oxymorphone—Flushing—Prednisone—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Oxymorphone—Headache—Azathioprine—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Oxymorphone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Oxymorphone—Dizziness—Leflunomide—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Oxymorphone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Oxymorphone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Oxymorphone—Angiopathy—Prednisone—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Oxymorphone—Immune system disorder—Prednisone—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Oxymorphone—Pain—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Oxymorphone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Oxymorphone—Vomiting—Leflunomide—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Oxymorphone—Hypersensitivity—Lisinopril—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Oxymorphone—Dizziness—Mycophenolic acid—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Oxymorphone—Dermatitis—Leflunomide—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Oxymorphone—Mental disorder—Prednisone—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Oxymorphone—Nausea—Azathioprine—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Oxymorphone—Headache—Leflunomide—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Oxymorphone—Malnutrition—Prednisone—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Oxymorphone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Oxymorphone—Asthenia—Lisinopril—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Oxymorphone—Pruritus—Lisinopril—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Oxymorphone—Vomiting—Mycophenolic acid—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Oxymorphone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Oxymorphone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Oxymorphone—Headache—Mycophenolic acid—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Oxymorphone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Oxymorphone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Oxymorphone—Nausea—Leflunomide—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Oxymorphone—Urinary tract disorder—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Oxymorphone—Vision blurred—Prednisone—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Oxymorphone—Urethral disorder—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Oxymorphone—Diarrhoea—Lisinopril—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Oxymorphone—Visual impairment—Methotrexate—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Oxymorphone—Agitation—Prednisone—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Oxymorphone—Dizziness—Lisinopril—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Oxymorphone—Nausea—Mycophenolic acid—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Oxymorphone—Vertigo—Prednisone—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Oxymorphone—Eye disorder—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Oxymorphone—Syncope—Prednisone—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Oxymorphone—Cardiac disorder—Methotrexate—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Oxymorphone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Oxymorphone—Loss of consciousness—Prednisone—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Oxymorphone—Vomiting—Lisinopril—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Oxymorphone—Angiopathy—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Oxymorphone—Immune system disorder—Methotrexate—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Convulsion—Prednisone—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Dermatitis—Lisinopril—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Mediastinal disorder—Methotrexate—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Hypertension—Prednisone—systemic scleroderma	0.001	0.001	CcSEcCtD
Oxymorphone—Headache—Lisinopril—systemic scleroderma	0.000997	0.000997	CcSEcCtD
Oxymorphone—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000986	0.000986	CcSEcCtD
Oxymorphone—Anxiety—Prednisone—systemic scleroderma	0.000982	0.000982	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000979	0.000979	CcSEcCtD
Oxymorphone—Mental disorder—Methotrexate—systemic scleroderma	0.000974	0.000974	CcSEcCtD
Oxymorphone—Malnutrition—Methotrexate—systemic scleroderma	0.000968	0.000968	CcSEcCtD
Oxymorphone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000954	0.000954	CcSEcCtD
Oxymorphone—Nausea—Lisinopril—systemic scleroderma	0.000945	0.000945	CcSEcCtD
Oxymorphone—Oedema—Prednisone—systemic scleroderma	0.000945	0.000945	CcSEcCtD
Oxymorphone—Shock—Prednisone—systemic scleroderma	0.00093	0.00093	CcSEcCtD
Oxymorphone—Nervous system disorder—Prednisone—systemic scleroderma	0.000927	0.000927	CcSEcCtD
Oxymorphone—Tachycardia—Prednisone—systemic scleroderma	0.000922	0.000922	CcSEcCtD
Oxymorphone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000922	0.000922	CcSEcCtD
Oxymorphone—Skin disorder—Prednisone—systemic scleroderma	0.000918	0.000918	CcSEcCtD
Oxymorphone—Hyperhidrosis—Prednisone—systemic scleroderma	0.000914	0.000914	CcSEcCtD
Oxymorphone—Vision blurred—Methotrexate—systemic scleroderma	0.000912	0.000912	CcSEcCtD
Oxymorphone—Anorexia—Prednisone—systemic scleroderma	0.000901	0.000901	CcSEcCtD
Oxymorphone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000886	0.000886	CcSEcCtD
Oxymorphone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000878	0.000878	CcSEcCtD
Oxymorphone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000873	0.000873	CcSEcCtD
Oxymorphone—Vertigo—Methotrexate—systemic scleroderma	0.000869	0.000869	CcSEcCtD
Oxymorphone—Insomnia—Prednisone—systemic scleroderma	0.000855	0.000855	CcSEcCtD
Oxymorphone—Convulsion—Methotrexate—systemic scleroderma	0.000838	0.000838	CcSEcCtD
Oxymorphone—Dyspepsia—Prednisone—systemic scleroderma	0.000832	0.000832	CcSEcCtD
Oxymorphone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000828	0.000828	CcSEcCtD
Oxymorphone—Chest pain—Methotrexate—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Oxymorphone—Decreased appetite—Prednisone—systemic scleroderma	0.000821	0.000821	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000818	0.000818	CcSEcCtD
Oxymorphone—Fatigue—Prednisone—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Oxymorphone—Constipation—Prednisone—systemic scleroderma	0.000808	0.000808	CcSEcCtD
Oxymorphone—Confusional state—Methotrexate—systemic scleroderma	0.000796	0.000796	CcSEcCtD
Oxymorphone—Feeling abnormal—Prednisone—systemic scleroderma	0.000779	0.000779	CcSEcCtD
Oxymorphone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000774	0.000774	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000773	0.000773	CcSEcCtD
Oxymorphone—Skin disorder—Methotrexate—systemic scleroderma	0.000767	0.000767	CcSEcCtD
Oxymorphone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000763	0.000763	CcSEcCtD
Oxymorphone—Anorexia—Methotrexate—systemic scleroderma	0.000753	0.000753	CcSEcCtD
Oxymorphone—Urticaria—Prednisone—systemic scleroderma	0.000751	0.000751	CcSEcCtD
Oxymorphone—Abdominal pain—Prednisone—systemic scleroderma	0.000747	0.000747	CcSEcCtD
Oxymorphone—Body temperature increased—Prednisone—systemic scleroderma	0.000747	0.000747	CcSEcCtD
Oxymorphone—Hypotension—Methotrexate—systemic scleroderma	0.000738	0.000738	CcSEcCtD
Oxymorphone—Insomnia—Methotrexate—systemic scleroderma	0.000714	0.000714	CcSEcCtD
Oxymorphone—Dyspnoea—Methotrexate—systemic scleroderma	0.000704	0.000704	CcSEcCtD
Oxymorphone—Somnolence—Methotrexate—systemic scleroderma	0.000702	0.000702	CcSEcCtD
Oxymorphone—Hypersensitivity—Prednisone—systemic scleroderma	0.000696	0.000696	CcSEcCtD
Oxymorphone—Dyspepsia—Methotrexate—systemic scleroderma	0.000695	0.000695	CcSEcCtD
Oxymorphone—Decreased appetite—Methotrexate—systemic scleroderma	0.000687	0.000687	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000682	0.000682	CcSEcCtD
Oxymorphone—Fatigue—Methotrexate—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Oxymorphone—Asthenia—Prednisone—systemic scleroderma	0.000678	0.000678	CcSEcCtD
Oxymorphone—Pain—Methotrexate—systemic scleroderma	0.000675	0.000675	CcSEcCtD
Oxymorphone—Pruritus—Prednisone—systemic scleroderma	0.000669	0.000669	CcSEcCtD
Oxymorphone—Feeling abnormal—Methotrexate—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Oxymorphone—Diarrhoea—Prednisone—systemic scleroderma	0.000647	0.000647	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Oxymorphone—Urticaria—Methotrexate—systemic scleroderma	0.000627	0.000627	CcSEcCtD
Oxymorphone—Dizziness—Prednisone—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Oxymorphone—Body temperature increased—Methotrexate—systemic scleroderma	0.000624	0.000624	CcSEcCtD
Oxymorphone—Abdominal pain—Methotrexate—systemic scleroderma	0.000624	0.000624	CcSEcCtD
Oxymorphone—Vomiting—Prednisone—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Oxymorphone—Dermatitis—Prednisone—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Oxymorphone—Headache—Prednisone—systemic scleroderma	0.000592	0.000592	CcSEcCtD
Oxymorphone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000582	0.000582	CcSEcCtD
Oxymorphone—Asthenia—Methotrexate—systemic scleroderma	0.000567	0.000567	CcSEcCtD
Oxymorphone—Nausea—Prednisone—systemic scleroderma	0.000561	0.000561	CcSEcCtD
Oxymorphone—Pruritus—Methotrexate—systemic scleroderma	0.000559	0.000559	CcSEcCtD
Oxymorphone—Diarrhoea—Methotrexate—systemic scleroderma	0.00054	0.00054	CcSEcCtD
Oxymorphone—Dizziness—Methotrexate—systemic scleroderma	0.000522	0.000522	CcSEcCtD
Oxymorphone—Vomiting—Methotrexate—systemic scleroderma	0.000502	0.000502	CcSEcCtD
Oxymorphone—Dermatitis—Methotrexate—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Oxymorphone—Headache—Methotrexate—systemic scleroderma	0.000495	0.000495	CcSEcCtD
Oxymorphone—Nausea—Methotrexate—systemic scleroderma	0.000469	0.000469	CcSEcCtD
